FLK1 Antibody VEGFR2 Polyclonal Antibody

	Catalog No	Formulation	Size	Price (USD)
	F50626-0.4ML	In 1X PBS, pH 7.4, with 0.09% sodium azide	0.4 ml	439
Formulation
	F50626-0.08ML	In 1X PBS, pH 7.4, with 0.09% sodium azide	0.08 ml	205
Formulation

FLK1 Antibody in HeLa Cells IF. Immunofluorescence staining of HeLa cells with FLK1 Antibody followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG, with DAPI used as a nuclear counterstain. Green VEGFR2 immunoreactivity is distributed through the cytoplasm and around the cell periphery, while nuclei are stained blue. The punctate to granular cellular signal and comparatively low background demonstrate detection of VEGFR2 in HeLa cells with the VEGFR2 Polyclonal Antibody.

FLK1 Antibody in Human Breast Carcinoma IHC. Immunohistochemistry staining of FFPE human breast carcinoma tissue with FLK1 Antibody. Brown immunoreactivity is readily visible in malignant epithelial cells, with staining distributed through the cytoplasm and along portions of the cell periphery. The surrounding stromal regions show comparatively less staining, providing contrast with the labeled tumor cells. This breast carcinoma staining supports tissue detection of VEGFR2 with the VEGFR2 Polyclonal Antibody.

FLK1 Antibody in MDA-MB435 Cells FACS. Flow cytometry analysis of MDA-MB435 cells with FLK1 Antibody followed by FITC-conjugated goat anti-rabbit secondary antibody. Antibody-stained cells show a pronounced rightward fluorescence shift compared with the negative control population, with clear separation between the two distributions. The strong shift demonstrates cellular detection of VEGFR2 and supports flow cytometry use of the VEGFR2 Polyclonal Antibody.

FLK1 Antibody in HeLa Cells WB. Western blot testing of HeLa cell lysate with FLK1 Antibody. A prominent high-molecular-weight band is detected at approximately 150 kDa, consistent with the predicted approximately 152 kDa immature form of VEGFR2. VEGFR2 undergoes extensive post-translational processing and glycosylation, with intermediate and mature receptor forms reported at approximately 180-200 kDa and 220-230 kDa, respectively. The observed target-sized signal demonstrates endogenous receptor detection and western blot performance of the VEGFR2 Polyclonal Antibody.

›

FLK1 Antibody in HeLa Cells IF. Immunofluorescence staining of HeLa cells with FLK1 Antibody followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG, with DAPI used as a nuclear counterstain. Green VEGFR2 immunoreactivity is distributed through the cytoplasm and around the cell periphery, while nuclei are stained blue. The punctate to granular cellular signal and comparatively low background demonstrate detection of VEGFR2 in HeLa cells with the VEGFR2 Polyclonal Antibody.

FLK1 Antibody in Human Breast Carcinoma IHC. Immunohistochemistry staining of FFPE human breast carcinoma tissue with FLK1 Antibody. Brown immunoreactivity is readily visible in malignant epithelial cells, with staining distributed through the cytoplasm and along portions of the cell periphery. The surrounding stromal regions show comparatively less staining, providing contrast with the labeled tumor cells. This breast carcinoma staining supports tissue detection of VEGFR2 with the VEGFR2 Polyclonal Antibody.

FLK1 Antibody in MDA-MB435 Cells FACS. Flow cytometry analysis of MDA-MB435 cells with FLK1 Antibody followed by FITC-conjugated goat anti-rabbit secondary antibody. Antibody-stained cells show a pronounced rightward fluorescence shift compared with the negative control population, with clear separation between the two distributions. The strong shift demonstrates cellular detection of VEGFR2 and supports flow cytometry use of the VEGFR2 Polyclonal Antibody.

FLK1 Antibody in HeLa Cells WB. Western blot testing of HeLa cell lysate with FLK1 Antibody. A prominent high-molecular-weight band is detected at approximately 150 kDa, consistent with the predicted approximately 152 kDa immature form of VEGFR2. VEGFR2 undergoes extensive post-translational processing and glycosylation, with intermediate and mature receptor forms reported at approximately 180-200 kDa and 220-230 kDa, respectively. The observed target-sized signal demonstrates endogenous receptor detection and western blot performance of the VEGFR2 Polyclonal Antibody.

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Host	Rabbit
Clonality	Polyclonal (rabbit origin)
Isotype	Rabbit Ig
Purity	Purified
UniProt	P35968
Localization	Cytoplasmic and cell surface
Applications	Western Blot : 1:1000 Immunofluorescence : 1:10-1:50 Flow Cytometry : 1:10-1:50 IHC (Paraffin) : 1:50-1:100
Limitations	This FLK1 Antibody / VEGFR2 Polyclonal Antibody is available for research use only.
	Review this product on BioCompare and get a $20 Amazon gift card

Description

FLK1 Antibody / VEGFR2 Polyclonal Antibody recognizes vascular endothelial growth factor receptor 2, a receptor tyrosine kinase that mediates many of the biological effects of VEGF. The receptor is encoded by KDR in humans and is commonly known as VEGFR2 or CD309. Flk1 is the historical designation widely used for the corresponding mouse receptor and remains common terminology in developmental and vascular biology literature.

VEGFR2 is a single-pass transmembrane protein with an extracellular ligand-binding region and an intracellular split tyrosine kinase domain. Binding of VEGF promotes receptor dimerization and activation of its kinase activity, resulting in phosphorylation of intracellular tyrosine residues. These sites recruit signaling proteins that connect VEGFR2 activation with pathways controlling endothelial cell behavior.

VEGFR2 signaling regulates endothelial cell proliferation, migration, survival and vascular permeability. Important downstream mechanisms include phospholipase C gamma and MAPK/ERK signaling together with PI3K/AKT and other regulatory pathways. These responses make VEGFR2 a central mediator of blood vessel formation and remodeling during development and in adult tissues.

The VEGF-VEGFR2 signaling axis is also important in pathological angiogenesis. Increased VEGF activity can promote formation of tumor-associated vasculature, while abnormal receptor signaling contributes to disorders involving vascular growth and permeability. VEGFR2 is consequently an important research target in cancer biology, angiogenesis and development of therapies designed to alter vascular signaling.

NSJ Bioreagents offers this FLK1 Antibody for research into VEGFR2 expression, VEGF signaling and vascular biology. Although FLK1 is most closely associated with the mouse receptor nomenclature, the term has a long history in the VEGFR2 literature. The VEGFR2 Polyclonal Antibody terminology provides the broadly recognized receptor designation across contemporary research.

An FLK1 Antibody provides a polyclonal reagent for investigating VEGFR2 biology using this established historical nomenclature, while a VEGFR2 Polyclonal Antibody supports research into angiogenesis, endothelial signaling and VEGF-dependent pathways.

For another antibody targeting the same receptor, see our VEGFR2 Antibody / KDR Polyclonal Antibody.

Application Notes

Titration of the FLK1 Antibody / VEGFR2 Polyclonal Antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Immunogen

A portion of amino acids 1326-1356 from the human protein was used as the immunogen for this VEGFR2 / FLK1 antibody.

Storage

Aliquot the VEGFR2 / FLK1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Alternate Names

VEGFR2 antibody, KDR antibody, VEGF Receptor 2 antibody, Vascular Endothelial Growth Factor Receptor 2 antibody, CD309 antibody, Kinase Insert Domain Receptor antibody

Related Products

1. View all VEGFR2 antibodies

FLK1 Antibody / VEGFR2 Polyclonal Antibody (F50626)

Description

Application Notes

Immunogen

Storage

Alternate Names

Related Products

Area of Research

Product Type

Protocols

Contact Us

NSJ Bioreagents